|
| 151例乳腺癌患者骨丢失及药物防治现况调查 |
| Investigation of bone loss and drug control in 151 patients with breast cancer |
| |
| DOI：10.3969/j.issn.1006.7108.2017.11.017 |
| 中文关键词: 乳腺癌 骨丢失 药物防治 骨质疏松 |
| 英文关键词:Breast cancer Bone loss Drug control Osteoporosis |
| 基金项目:新疆医科大学科研创新基金项目（ZYY201604) |
|
| 摘要点击次数: 602 |
| 全文下载次数: 546 |
| 中文摘要: |
| 目的 调查乳腺癌患者骨健康状况及药物防治现况。方法 对151例女性乳腺癌患者进行回顾性研究，记录患者年龄、体质量指数、骨密度和药物干预情况的信息，所有数据用Excel表格进行处理。结果 151例女性乳腺癌患者中，骨质疏松发生率为22. 52%(34/151)，唑来膦酸联合钙剂和维生素D制剂构成骨质疏松药物治疗方案；骨量减少发生率为30.46% (46/151)，其中符合相关指南推荐的合并2个危险因素的中危患者，药物治疗方案为口服钙剂和维生素D制剂，未使用唑来膦酸。结论 临床应综合骨密度、FRAX评分及患者个体情况，加强对乳腺癌患者骨折风险评估及防治。 |
| 英文摘要: |
| Objective To investigate the bone health status of breast cancer patients and the current situation of drug control. Methods A retrospective study was conducted in 151 female breast cancer patients. Age，body mass index，bone mineral density，and drug intervention of the patients were recorded. All the data were processed with an Excel table. Results Among 151 female breast cancer patients，the incidence of osteoporosis was 22. 52% (34/151). After the application of zoledronic acid combined with calcium and vitamin D，bone loss rate was dropped to 30. 46% (46/151). The patients who had two risk factors received oral calcium and vitamin D，according to the guideline，without use of zoledronic acid. Conclusion The clinical assessment of patients with fracture risk should be strengthened based on comprehensive evaluation of bone mineral density，FRAX score，and individual situation. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |